Week of June 29, 2026

This week ending June 29, 2026, biotech specialist funds remain highly active ahead of a dense catalyst calendar, with several binary readouts landing at the close of the quarter. The most immediate event to watch is Sanofi's Phase 3 data for amlitelimab (SNYNF), which hit today, followed by a trio of Phase 2 and Phase 3 readouts due June 30 spanning Amgen (AMGN) with its 9-microgram blinatumomab dose-optimization study, Agios Pharmaceuticals (AGIO) with mitapivat data, United Therapeutics (UTHR) with linaclotide, and AstraZeneca (AZN) with its durvalumab Phase 3 program. The concentration of end-of-quarter readouts is a familiar pattern, and positioning data suggests funds have been building or trimming exposure accordingly in the days leading up to these events.

On the convergence front, Structure Therapeutics (GPCR) stands out as one of the most crowded high-conviction names in the specialist universe, with 10 funds holding a combined $1.0 billion in the stock. Equally notable is COMPASS Pathways (CMPS), also held by 10 funds with aggregate exposure of approximately $454.5 million, reflecting sustained institutional interest in the neuropsychiatry space as the regulatory and commercial narrative around psilocybin-based therapeutics continues to develop. Centessa Pharmaceuticals (CNTA) carries the highest aggregate dollar conviction among the top convergence names, with 9 funds collectively holding $1.2 billion, suggesting meaningful confidence in its multi-asset pipeline ahead of anticipated clinical milestones later this year.

Rounding out the high-convergence signals, Xenon Pharmaceuticals (XENE) is held by 9 funds at a combined $891.2 million, underscoring continued fund appetite for precision ion channel neurology plays, while Celcuity (CELC) commands the single largest pooled position among convergence names at $2.4 billion across 8 funds — a figure that reflects deep conviction in its PI3K-alpha inhibitor gedatolisib combination strategy in breast cancer. When multiple specialist funds, each conducting independent due diligence, arrive at the same name at scale, it historically serves as a meaningful signal worth tracking closely. CELC in particular warrants attention given the magnitude of concentrated institutional capital relative to its peer group.

Taken together, this week's positioning landscape reflects a biotech fund community balancing near-term binary risk around catalyst-heavy large- and mid-cap names with longer-duration bets concentrated in